Guided Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Guided Therapeutics Inc (GTHP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Guided Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 201,292M combined for its competitors (0.0% combined share).
- Scale: Guided Therapeutics Inc ranks #165 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer differentiation: Revenue per employee of $0.05M compares with $0.38M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Guided Therapeutics Inc vs. its Competitors, Q2 2026
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Guided Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Guided Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Guided Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Guided Therapeutics Inc's competitor groups requires a Commercial License.
Guided Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Guided Therapeutics Inc | No | Yes | Yes | Yes |
| Competitors combined (27) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GTHP Stock Performance relative to its Competitors
GTHP Stock Performance relative to High-Confidence Competitors
GTHP Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Pulse Biosciences Inc | 282.9% | Outperformed |
| 2 | Becton Dickinson And Company | 282.9% | Outperformed |
| 3 | Orasure Technologies Inc | 282.9% | Outperformed |
| 4 | Profound Medical Corp | 282.9% | Outperformed |
| 5 | Thermo Fisher Scientific Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Guided Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Guided Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Guided Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Guided Therapeutics Inc |
10.62 | 0.16 |
 Thermo Fisher Scientific Inc |
266,452.20 | 47,351.00 |
 Abbott Laboratories |
191,969.10 | 48,229.00 |
 Danaher Corporation |
166,932.02 | 25,608.00 |
 Medtronic Plc |
130,553.31 | 37,542.00 |
 Boston Scientific Corporation |
64,904.40 | 21,070.00 |
| SUBTOTAL | 915,218.58 | 207,537.51 |
Sign in to see all competitors of Guided Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Guided Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Guided Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Guided Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Hologic | Company report | 85% |
| Spectrascience | Company report | 85% |
| Qiagen | Company report | 85% |
| Dysis | Company report | 85% |
| Zedco | Company report | 85% |
| Roche | Company report | 85% |
| Iridex Corp | Company report | 85% |
| Escalon Medical Corp | Company report | 85% |
| Becton Dickinson And Company | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Lensar Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Imaging Diagnostic Systems Inc | Company report | 85% |
| Motus Gi Holdings Inc | Company report | 85% |
| Danaher Corporation | Company report | 85% |
| Orasure Technologies Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Guided Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Guided Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Thermo Fisher Scientific Inc | Clinical Research 20.15 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
| Danaher Corporation | Diagnostics 43.97 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Boston Scientific Corporation | Cardiovascular 66.29 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Guided Therapeutics Inc .
Guided Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Guided Therapeutics Inc | 11 | 53,667 | -1,190,333 |
| Thermo Fisher Scientific Inc | 266,452 | 378,808 | 56,712 |
| Abbott Laboratories | 191,969 | 419,383 | 40,878 |
| Danaher Corporation | 166,932 | 426,800 | 72,183 |
| Medtronic Plc | 130,553 | 395,179 | 55,463 |
| Boston Scientific Corporation | 64,904 | 357,119 | 59,220 |
| PEERS TOTAL | 915,208 | 382,757 | 48,651 |
Sign in to see all peers for Guided Therapeutics Inc .
Guided Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Thermo Fisher Scientific Inc | North America 51.63 % |
| Abbott Laboratories | Non-US 57.70 % |
| Danaher Corporation | North America 41.81 % |
| Medtronic Plc | United States 49.83 % |
| Boston Scientific Corporation | United States 64.40 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Guided Therapeutics Inc .
Guided Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Guided Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Guided Therapeutics Inc ranks #165 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 606, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 162,645 | 13.42 % |
| 2 | Medtronic Plc | 130,990 | 10.81 % |
| 3 | Stryker Corp | 124,012 | 10.23 % |
| 4 | 3m Company | 98,566 | 8.13 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Medline Inc | 1,234 | 5.2% |
| 10 | Resmed Inc | 1,234 | 5.2% |
| 165 | Guided Therapeutics Inc | 13 | 0.00 % |
Market cap and industry share for the rest of Guided Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-10.
Guided Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 160 | Beyond Air Inc | 18 | 40.34 % |
| 161 | Retractable Technologies Inc | 17 | -31.71 % |
| 162 | Sanuwave Health Inc | 17 | -92.97 % |
| 163 | Lifeward ltd | 16 | -11.55 % |
| 164 | Picard Medical Inc | 1,234 | 12.3% |
| 165 | Guided Therapeutics Inc | 13 | -44.80 % |
| 166 | P3 Health Partners Inc | 1,234 | 12.3% |
| 167 | Iridex Corp | 1,234 | 12.3% |
| 168 | Endra Life Sciences Inc | 1,234 | 12.3% |
| 169 | Accuray Incorporated | 1,234 | 12.3% |
| 170 | United Health Products Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Guided Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-10. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Guided Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.76 % | 46.20 % (avg) | -45.4 pp |
| Operating Margin | -3.79 % | industry median | -3.7 pp |
| EBITDA Margin | -3.47 % | -6.66 % (avg) | +3.2 pp |
| Capital Intensity (Capex / Revenue) | - | 7.13 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Guided Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 36.9x | - |
| EV / EBITDA | - | 17.8x | - |
| P/B | -3.7x | 4.6x | -8.3x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -6.78 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Guided Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -59.67 % | - | - | - | - | - | - | - |
| Operating Margin | -1,279.10 % | - | - | -2,916.05 % | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Guided Therapeutics Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Guided Therapeutics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.9% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Guided Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 606 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Guided Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Guided Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Guided Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Guided Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Guided Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Guided Therapeutics Inc | - | 0.11 | - |
| Thermo Fisher Scientific Inc | 0.39 | 1.69 | 0.81 |
| Abbott Laboratories | 0.36 | 1.45 | 0.53 |
| Danaher Corporation | - | 1.75 | 0.45 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Boston Scientific Corporation | 0.23 | 1.50 | 0.46 |
Sign in to see all peers for Guided Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Guided Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Guided Therapeutics Inc | Q2 2026 | - | - |
| Thermo Fisher Scientific Inc | Q3 2026 | +9.1 % | +6.2 % |
| Abbott Laboratories | Q3 2026 | +14.5 % | -44.0 % |
| Danaher Corporation | Q3 2026 | +8.3 % | +36.0 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Boston Scientific Corporation | Q3 2026 | +1.4 % | -23.2 % |
| PEERS TOTAL | +10.0 % | -0.9 % |
Sign in to see all peers for Guided Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Guided Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Guided Therapeutics Inc | Q2 2026 | - | - |
| Thermo Fisher Scientific Inc | Q3 2026 | +133.0 % | +8.2 % |
| Abbott Laboratories | Q3 2026 | +10.9 % | +3.4 % |
| Danaher Corporation | Q3 2026 | +7.4 % | -12.7 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Boston Scientific Corporation | Q3 2026 | +12.3 % | -0.6 % |
Sign in to see all peers for Guided Therapeutics Inc .
Guided Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Guided Therapeutics Inc | - | - | - |
| Thermo Fisher Scientific Inc | 6.29% | 7.46% | 13.32% |
| Abbott Laboratories | 4.54% | 5.14% | 9.00% |
| Danaher Corporation | 4.91% | 5.57% | 8.18% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Boston Scientific Corporation | 7.82% | 9.14% | 13.75% |
Sign in to see all peers for Guided Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Guided Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Guided Therapeutics Inc | - | 65.96 |
| Thermo Fisher Scientific Inc | 37.96 | 5.63 |
| Abbott Laboratories | 40.91 | 3.98 |
| Danaher Corporation | 38.72 | 6.52 |
| Medtronic Plc | 298.79 | 3.48 |
| Boston Scientific Corporation | 18.97 | 3.08 |
| PEERS AVERAGE | 34.70 | 4.41 |
Sign in to see all peers for Guided Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.